The combination of the MEK inhibitor Cobimetinib and BRAF inhibitor Vemurafenib with anti-PD-1 antibody Atezolizumab showed better PFS in patients with metastatic MM than those treated with Cobimetinib and Vemurafenib [111]. This evidence concerns the gene BRAF and Miyoshi myopathy.